These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29872580)

  • 1. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
    Luo N; Formisano L; Gonzalez-Ericsson PI; Sanchez V; Dean PT; Opalenik SR; Sanders ME; Cook RS; Arteaga CL; Johnson DB; Balko JM
    Oncoimmunology; 2018; 7(6):e1438106. PubMed ID: 29872580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses.
    Ravindran Menon D; Li Y; Yamauchi T; Osborne DG; Vaddi PK; Wempe MF; Zhai Z; Fujita M
    Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.
    Bellucci R; Martin A; Bommarito D; Wang K; Hansen SH; Freeman GJ; Ritz J
    Oncoimmunology; 2015 Jun; 4(6):e1008824. PubMed ID: 26155422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade.
    Vackova J; Piatakova A; Polakova I; Smahel M
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
    Iwasaki T; Kohashi K; Toda Y; Ishihara S; Yamada Y; Oda Y
    J Cancer Res Clin Oncol; 2021 May; 147(5):1451-1463. PubMed ID: 32951108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression increased by IFN-γ via JAK2-STAT1 signaling and predicts a poor survival in colorectal cancer.
    Zhao T; Li Y; Zhang J; Zhang B
    Oncol Lett; 2020 Aug; 20(2):1127-1134. PubMed ID: 32724352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
    Deepak HB; Prince SE; Deshpande P
    Indian J Pharmacol; 2022; 54(3):183-193. PubMed ID: 35848689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
    Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor.
    Ge T; Phung AL; Jhala G; Trivedi P; Principe N; De George DJ; Pappas EG; Litwak S; Sanz-Villanueva L; Catterall T; Fynch S; Boon L; Kay TW; Chee J; Krishnamurthy B; Thomas HE
    Clin Transl Immunology; 2022; 11(11):e1425. PubMed ID: 36325490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.
    Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J
    Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-γ treatment protocol for MHC-I
    Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway.
    Xue W; Li W; Zhang T; Li Z; Wang Y; Qiu Y; Wang Y; Chen C; Fu D; Zhang M
    Onco Targets Ther; 2019; 12():2079-2088. PubMed ID: 30962691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state.
    Briscoe J; Rogers NC; Witthuhn BA; Watling D; Harpur AG; Wilks AF; Stark GR; Ihle JN; Kerr IM
    EMBO J; 1996 Feb; 15(4):799-809. PubMed ID: 8631301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
    Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
    Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [IFN-γ induces overexpression of PD-L1 and epithelialmesenchymal transformation of breast cancer cells through activating ERK/Jak2-STAT signaling pathways].
    Yan Y; Zhao C; Yang R; Zhou T; Xu N
    Sheng Wu Gong Cheng Xue Bao; 2018 Dec; 34(12):2007-2015. PubMed ID: 30584711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.
    Nguyen TT; Ramsay L; Ahanfeshar-Adams M; Lajoie M; Schadendorf D; Alain T; Watson IR
    Clin Cancer Res; 2021 Jun; 27(12):3432-3442. PubMed ID: 33593882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
    Knopf P; Stowbur D; Hoffmann SHL; Hermann N; Maurer A; Bucher V; Poxleitner M; Tako B; Sonanini D; Krishnamachary B; Sinharay S; Fehrenbacher B; Gonzalez-Menendez I; Reckmann F; Bomze D; Flatz L; Kramer D; Schaller M; Forchhammer S; Bhujwalla ZM; Quintanilla-Martinez L; Schulze-Osthoff K; Pagel MD; Fransen MF; Röcken M; Martins AF; Pichler BJ; Ghoreschi K; Kneilling M
    Mol Cancer; 2023 Dec; 22(1):207. PubMed ID: 38102680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.